ABSTRACT
Coronavirus has infected more than 753 million people, ranging in severity from one person to another, where more than six million infected people died worldwide. Computer-aided diagnostic (CAD) with artificial intelligence (AI) showed outstanding performance in effectively diagnosing this virus in real-time. Computed tomography is a complementary diagnostic tool to clarify the damage of COVID-19 in the lungs even before symptoms appear in patients. This paper conducts a systematic literature review of deep learning methods for classifying the segmentation of COVID-19 infection in the lungs. We used the methodology of systematic reviews and meta-analyses (PRISMA) flow method. This research aims to systematically analyze the supervised deep learning methods, open resource datasets, data augmentation methods, and loss functions used for various segment shapes of COVID-19 infection from computerized tomography (CT) chest images. We have selected 56 primary studies relevant to the topic of the paper. We have compared different aspects of the algorithms used to segment infected areas in the CT images. Limitations to deep learning in the segmentation of infected areas still need to be developed to predict smaller regions of infection at the beginning of their appearance.
ABSTRACT
Objectives: To assess the characteristics of FDA renal toxicity boxed warnings (formerly called Black Box Warning) included in the labels of drugs approved by the FDA and marked in the US. Method(s): We extracted the labels of human prescription drugs with renal toxicity boxed warnings from the "FDA Label: Full-Text Search of Drug Product Labeling" database, FDA regulatory information from drugs@FDA as of September 1, 2022. We extracted the therapeutic classification from the WHO ATC system. We conducted a descriptive analysis of the data. Result(s): The FDA listed 86 drugs including 72 active ingredients and 14 combinations with a boxed warning mentioning renal toxicity. Three drugs had emergency use authorizations for COVID-19, and all combinations included metformin. There were 8 (8.7%) drugs with renal toxicity boxed warnings approved before 1970, 6 (6.5%) in the 1970s, 14 (15.2%) in the 1980s, 34 (37.0%) in the 1990s, 17 (18.5%) in the 2000s, 9 (9.8%) in the 2010s, and 4 (4.3%) in 2020-Sep 2022. The therapeutic classes with the largest number of renal toxicity boxed warning included anti-infectives for systemic use 24 (26.1%), antineoplastic and immunomodulating agents 22 (23.9%), and alimentary tract and metabolism 17 (18.5%). The most common boxed warnings included renal impairment (n=21, 22.8%), nephrotoxicity (10, 10.9%), and nephrogenic systemic fibrosis (7, 7.6%). Additionally, 9 (9.8%) boxed warnings referred to the potential problems for patients with kidney transplants. Conclusion(s): Most drugs with a boxed warning were approved in the 1990s and 2000s. The therapeutic classes with the highest number of renal toxicity warnings were anti-infective for systemic use, antineoplastic and immunomodulating agents, and alimentary tract and metabolism. The most common warnings were renal impairment, nephrotoxicity, nephrogenic systemic fibrosis, and issues for patients with kidney transplants. Future research could expand the analysis to renal toxicity warnings, interactions, and precautions.Copyright © 2023
ABSTRACT
Wearing face masks have been implemented as a public and personal health control measure against the spread of coronavirus disease (COVID-19). However, the protection level of non-medical face masks, such as women face veils, is still uncertain. This study aimed to assess the filtration efficiency (FE;percentage of particles retained by a mask) of different types of medical masks (either as sealed or unsealed, single or doubled), non-medical masks (cloth masks) and face veils. FE of face masks was evaluated using an in-house 3D-printed air duct connected to the Aerotrak particle counter with a capability of counting particle sizes of 0.3, 0.5, 0.7, 1, 2 and 5 mu m. A set of 10 earloop surgical masks,10 tie-on surgical masks, 3 triple-layers reusable cloth masks and 3 types (short, medium and long) of traditional face veils were included in the study. The unsealed surgical masks showed intermediate FE (36.54-80.58%), with no observed differences between tie-on and earloop or single and doubled masks. For each mask type, the mean FE values of sealed surgical masks (FE=99.16%) was significantly higher (P<0.001) than the unsealed ones (FE=80.58%). No significant difference was observed in the mean FE values between unsealed surgical masks and either cloth masks (FE=23.19-75.35%, P=0.26) or face veils (FE=19.10-70.68%, P=0.14). However, a mockup experiment showed that wearing a surgical mask under the face veil significantly improve the FE (33.73-79.18%;P<0.001). We conclude that besides sealed surgical masks that ensure optimal filtration under the experimental conditions, the unsealed surgical and cloth masks and face veils showed comparable performance and acceptable protection at 5 mu m particle size, which is the most relevant particle size associated with COVID-19 infectious droplets. Wearing a surgical mask under the face veil significantly improves the FE compared to wearing a face veil alone.
ABSTRACT
Context . RNA viruses exhibit an extraordinary ability to evolve in a changing environment and to switch from animal hosts to humans. The ongoing COVID-19 pandemic, recognized as a respiratory disease, is an example of zoonotic transmission of the RNA virus known as SARS-CoV-2. The development and regulatory approval of a vaccine against SARS-CoV-2 pose multiple preventive and therapeutic challenges, especially during an ongoing pandemic. Objective . The review intended to examine the challenges and recent achievements in the development of vaccine candidates against COVID-19. Design . The research team performed a literature review, searching relevant and up to date information from the literature. The sources of data included Google Scholar, PubMed, NCBI, and Yahoo. The search terms used were COVID-19 challenges, SARS-CoV-2 prospective challenges, RNA viruses adoptability, host switching by RNA viruses, COVID-19 vaccines. Setting . The study took place at the digital libraries of contributing institutions. The data was combined, selected for further analysis and manuscript preparation at King Abdulaziz University. Results . RNA viruses with high rate of genome alterations and evolution have better chances to survive in the adverse environmental conditions by adopting the alternate host species. The recent epidemics such as SARS, MERS, and COVID-19 are examples of zoonotic transmission of RNA viruses from animal species to the humans. However, the mechanisms involved in the switching-on to new host species need further investigations to control the zoonotic transmissions in near future. As of April 2020, 115 candidate vaccines were being evaluated;78 of them had been found to be active, and a few of them are in Phase I trials. In the development of different types of vaccine candidates against COVID19, multiple international pharmaceutical and biotechnology companies are involved. Conclusions . Emerging and re-emerging pathogenic RNA viruses pose a serious threat to human health. Little is known about the human-host adoptive mechanism for zoonotic transmission. Deep insights into the molecular mechanism responsible for the switching of animal or bird viruses to humans could provide target molecules or events to prevent such transmissions in the near future. Fast development and approval of efficacious and safe vaccines is key to the effort to provide preventive measures against COVID-19 and future viruses. However, the development and availability of a vaccine candidate is a time-consuming process and often can't be completed during an epidemic. Currently, several types of vaccines are under development, and most of them won't realistically be available in time for the present COVID-19 pandemic.
ABSTRACT
Context: RNA viruses exhibit an extraordinary ability to evolve in a changing environment and to switch from animal hosts to humans. The ongoing COVID-19 pandemic, recognized as a respiratory disease, is an example of zoonotic transmission of the RNA virus known as SARS-CoV-2. The development and regulatory approval of a vaccine against SARS-CoV-2 pose multiple preventive and therapeutic challenges, especially during an ongoing pandemic. Objective: The review intended to examine the challenges and recent achievements in the development of vaccine candidates against COVID-19. Design: The research team performed a literature review, searching relevant and up to date information from the literature. The sources of data included Google Scholar, PubMed, NCBI, and Yahoo. The search terms used were COVID-19 challenges, SARS-CoV-2 prospective challenges, RNA viruses adoptability, host switching by RNA viruses, COVID-19 vaccines. Setting: The study took place at the digital libraries of contributing institutions. The data was combined, selected for further analysis and manuscript preparation at King Abdulaziz University. Results: RNA viruses with high rate of genome alterations and evolution have better chances to survive in the adverse environmental conditions by adopting the alternate host species. The recent epidemics such as SARS, MERS, and COVID-19 are examples of zoonotic transmission of RNA viruses from animal species to the humans. However, the mechanisms involved in the switching-on to new host species need further investigations to control the zoonotic transmissions in near future. As of April 2020, 115 candidate vaccines were being evaluated;78 of them had been found to be active, and a few of them are in Phase I trials. In the development of different types of vaccine candidates against COVID-19, multiple international pharmaceutical and biotechnology companies are involved. Conclusions: Emerging and re-emerging pathogenic RNA viruses pose a serious threat to human health. Little is known about the human-host adoptive mechanism for zoonotic transmission. Deep insights into the molecular mechanism responsible for the switching of animal or bird viruses to humans could provide target molecules or events to prevent such transmissions in the near future. Fast development and approval of efficacious and safe vaccines is key to the effort to provide preventive measures against COVID-19 and future viruses. However, the development and availability of a vaccine candidate is a time-consuming process and often can't be completed during an epidemic. Currently, several types of vaccines are under development, and most of them won't realistically be available in time for the present COVID-19 pandemic.